Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing
Executive Summary
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
You may also be interested in...
Jefferies' Survey Predicts M&A Rebound In 2021
An upturn in M&A activity in the healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. There is also increasing interest in investing in China, according to the survey.
Finance Watch: Three New Life Science VC Funds Total Nearly $1bn
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten
Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.
Need a specific report? 1000+ reports available
Buy Reports